Morgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $99.00 price target on Viking Therapeutics (NASDAQ: VKTX)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE